Klopidogrel, the tab. п / about 75 mg No. 10*3

General characteristics. Structure:

Active agent: 1 tablet contains - клопидогреля bisulphate in terms of клопидогрель – 75 mg;

excipients: Mannitolum, the microcrystallic cellulose, hydroxypropyl cellulose low - replaced silicon dioxide colloid anhydrous, poleetilen-glycol 6000, the castor oil hydrogenated опадрай 85 G54240 pink.

Pharmacological properties:

Pharmacodynamics. Pharmacological action – anti-aggregation. Selectively it is also irreversible blocks linkng of adenosinediphosphate (ADF) with receptors of thrombocytes, oppresses them activation, reduces quantity functioning Adf-retseptorov (without damage), interferes with sorption of fibrinogen and inhibits aggregation of thrombocytes. Selectively inhibits activation of the GP II b/III a complex under the influence of ADF.

Pharmacokinetics. At intake it is quickly soaked up, characterized by high bioavailability. Time of achievement of Cmax makes about 1 h. Is premedicine, it biotransformirutsya in a liver with formation of an active metabolite (thiol derivative). The main metabolite – carboxyl derivative, has no activity. T1/2 makes about 8 h. It is removed with urine (50%) and excrements (46%). The inhibition of aggregation begins in 2 h after reception (40% of inhibition), is registered at an initial dose of 400 mg. The maximum effect (60% aggregation oppression) is observed in 4 - 7 days of constant reception in a dose of 50 - 100 mg/days Antiagregatsiynny effect the entire period of life of thrombocytes (7 - 10 days) remains. In the presence of atherosclerotic defeat of a vessel interferes with development of an aterotromboz, irrespective of the nature of vascular process (cerebrovascular, cardiovascular or peripheral defeats). At treatment klopidogrely in comparison with aspirin the relative total risk of an ischemic stroke decreases by 8,7%.

Indications to use:

Prevention of ischemic disturbances (myocardial infarction, ischemic stroke, thrombosis of peripheral arteries) at patients with atherosclerosis, an acute coronary syndrome without ST segment elevation.

Route of administration and doses:

Inside on 75 mg of 1 times a day irrespective of meal. Treatment needs to be begun from several days to 35 days at patients after a myocardial infarction and from 7 days to 6 months at patients after an ischemic stroke in time. There is no experience of use for children.

Features of use:

With care appoint the patient with the increased risk of bleeding (an injury, an operative measure, a coagulopathy, etc.). At treatment of patients with heavy abnormal liver functions it is necessary to consider a possibility of development of hemorrhagic diathesis. Safety and efficiency of use of drug for children are not established. Appointment at pregnancy and feeding as a breast only in urgent cases.

Side effects:

From the central nervous system – a headache, dizziness, paresthesia, confusion of consciousness, a hallucination, disturbance of flavoring feelings.
From digestive tract – abdominal pain, dyspepsia, gastritis, diarrhea, a konstipation, nausea, vomiting, a meteorism, a gastrointestinal hemorrhage.

Seldom – a Werlhof's disease. The neutropenia, an eosinophilia, skin rashes, palpitation, a syncope, an adynamy, neuralgia, paresthesia and вертиго are possible.

Contraindications:

Hypersensitivity, active bleedings (round ulcer or intracranial hemorrhage), serious illness of a liver, peptic ulcer of a stomach and duodenum.

Overdose:

Symptoms: lengthening of a bleeding time with further complications, dejectedness, the complicated breath, a gastrointestinal hemorrhage.

Treatment: a hemodialysis, transfusion of a platelet concentrate is possible.

Issue conditions:

According to the recipe